Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer

Head and Neck Surgery Branch, National Institute of Deafness and Communication Disorders, National Institutes of Health, Bethesda, MD, USA.
International journal of radiation oncology, biology, physics (Impact Factor: 4.26). 10/2009; 77(2):447-54. DOI: 10.1016/j.ijrobp.2009.05.037
Source: PubMed

ABSTRACT Epidermal growth factor receptor (EGFR) overexpression in head-and-neck squamous cell carcinoma (HNSCC) stimulates tumor cell proliferation, inhibits apoptosis, and increases chemotherapy and radiation resistance. We examined the toxicity, safety and the effects on EGFR signaling in tumor biopsy samples from patients with locally advanced HNSCC treated with the EGFR signaling inhibitor gefitinib (GEF) combined with weekly intravenous paclitaxel (PAC) and radiation therapy (RT).
This was a pilot Phase I dose-escalation study. Eligibility included Stage III to IVB HNSCC, age >or=18 years, no prior RT or chemotherapy, adequate organ function, and informed consent. Endpoints included determination of maximum tolerated dose (MTD) and analysis of treatment effect on EGFR signaling, tumor cell proliferation, and apoptosis in biopsy samples.
Ten patients were treated. The MTD of this combination was GEF 250 mg/d with PAC 36 mg/m(2) intravenously weekly x 6 with concurrent RT. Grade 3/4 toxicities included prolonged (>8 weeks) stomatitis (7 patients), infection (2 patients), and interstitial pneumonitis (1 patient). There were five complete responses (CR) and two partial responses (PR). Of 7 patients undergoing serial biopsies, only 1 patient demonstrated a reduction in phosphorylated EGFR, decreased downstream signaling, and reduced cellular proliferation after initiating GEF.
Inhibition of EGFR by GEF was observed in only one of seven tumors studied. The addition of GEF to PAC and RT did not appear to improve the response of locally advanced HNSCC compared with our prior experience with PAC and RT alone. This treatment appeared to delay recovery from stomatitis.

Download full-text


Available from: John C Morris, Sep 29, 2015
10 Reads
  • Source
    • "2010 I Glioma 55.8 Gy þ gefitinib Trial stopped early due to haemorrhage; later thought to be unrelated to gefitinib Gefitinib [23] 2010 I HNSCC IR þ paclitaxel þ gefitinib Toxicity limits clinical acceptability; no improvement in CRR Gefitinib [24] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent drug discovery developments in the field of small molecule targeted agents have led to much interest in combining these with radiotherapy. There are good preclinical data to suggest this approach worthy of investigation and in this review we discuss how this has translated into recent clinical trials. The outcome of clinical trials investigating radiotherapy/targeted drug combinations published in the last 5 years is discussed, as are trials in progress. The perceived future opportunities and challenges in the development of this exciting area are considered.
    Clinical Oncology 03/2014; 26(5). DOI:10.1016/j.clon.2014.02.006 · 3.40 Impact Factor
  • Source
    • "Head and neck squamous cell carcinomas (HNSCCs) have been the subject for clinical or preclinical studies of several targeted agents against a few commonly activated or inactivated pathways, including epidermal growth factor receptor (EGFR; cetuximab, gefitinib, and erlotinib) [1] [2] [3] [4] [5], proteasome-dependent nuclear factor κB (NF-κB) activation (bortezomib) [6] [7], signal transducer and transcription factor 3 (STAT3; decoy oligonucleotide) [8], and disrupted tumor suppressor TP53 (TP53 adenovirus) [9]. These agents have demonstrated significant target-specific and preclinical activity but modest clinical activity at achievable concentrations as monotherapy or in combination with conventional therapies [1] [2] [3] [4] [5] [6] [7] [8] [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Heat shock protein 90 (HSP90) is a chaperone protein that stabilizes proteins involved in oncogenic and therapeutic resistance pathways of epithelial cancers, including head and neck squamous cell carcinomas (HNSCCs). Here, we characterized the molecular, cellular, and preclinical activity of HSP90 inhibitor SNX5422/2112 in HNSCC overexpressing HSP90. SNX2112 inhibited proliferation, induced G2/M block, and enhanced cytotoxicity, chemosensitivity, and radiosensitivity between 25 and 250 nM in vitro. SNX2112 showed combinatorial activity with paclitaxel in wild-type (wt) TP53-deficient and cisplatin in mutant (mt) TP53 HNSCC lines. SNX2112 decreased expression or phosphorylation of epidermal growth factor receptor (EGFR), c-MET, v-akt murine thymoma viral oncogene homolog 1 (AKT), extracellular signal-regulated kinases (ERK) 1 and 2, inhibitor κB kinase, and signal transducer and transcription factor 3 (STAT3), corresponding downstream nuclear factor κB, activator protein-1, and STAT3 reporter genes, and target oncogenes and angiogenic cytokines. Furthermore, SNX2112 enhanced re-expression of TP53 and targets p21WAF1 and PUMA, while TP53 inhibitor Pifithrin or siRNA attenuated the antiproliferative activity of SNX2112 in wtTP53 HNSCC in vitro. Prodrug SNX5422 similarly down-modulated key signal targets, enhanced TP53 expression and apoptosis, and inhibited proliferation, angiogenesis, and tumorigenesis in a wtTP53-deficient HNSCC xenograft model. Thus, HSP90 inhibitor SNX5422/2112 broadly modulates multiple key nodes within the dysregulated signaling network, with corresponding effects upon the malignant phenotype. Our data support investigation of SNX5422/2112 in combination with paclitaxel, cisplatin, and radiotherapy in HNSCC with different TP53 status.
    Translational oncology 08/2013; 6(4):429-41. DOI:10.1593/tlo.13292 · 2.88 Impact Factor
  • Source
    • "SCC EGFR Cisplatin 2.0 Gy once daily/15 days, followed by 1.4 Gy twice daily/15 days Definitive Safety and tolerability Toxicity and response determined Active and well tolerated combination I 2010 [28] SCC EGFR Docetaxel 1.8 Gy once daily/38 days Local disease control Safety and efficacy Toxicity and response determined Unclear whether any additional response II 2009 [29] SCC EGFR Paclitaxel 1.8 Gy once daily/37– 42 days Local disease control Safety, tolerability, and efficacy DLT, MTD, and response determined No additional response I 2010 [30] SCC EGFR "
    [Show abstract] [Hide abstract]
    ABSTRACT: New strategies to facilitate the improvement of physical and integrated biological optimization of high-precision treatment protocols are an important priority for modern radiation oncology. From a clinical perspective, as knowledge accumulates from molecular radiobiology, there is a complex and exciting opportunity to investigate novel approaches to rational patient treatment stratification based on actionable tumor targets, together with the appropriate design of next-generation early-phase radiotherapy trials utilizing targeted therapeutics, to formally evaluate relevant clinical and biomarker endpoints. A unique aspect in the development pathway of systemic agents with presumed radiosensitizing activity will also be the need for special attention on patient eligibility and the rigorous definition of radiation dose-volume relationships and potential dose-limiting toxicities. Based on recent experience from systematically investigating histone deacetylase inhibitors as radiosensitizing agents, from initial studies in preclinical tumor models through the conduct of a phase I clinical study to evaluate tumor activity of the targeted agent as well as patient safety and tumor response to the combined treatment modality, this communication will summarize principles relating to early clinical evaluation of combining radiotherapy and targeted therapeutics.
    Radiotherapy and Oncology 07/2013; 108(1). DOI:10.1016/j.radonc.2013.06.007 · 4.36 Impact Factor
Show more